Quidditas Therapeutics develops an alternative technology which permits an absolute genetic recombination.
Quidditas Therapeutics has raised $1.9M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
Quidditas Therapeutics's investors include IncubAlliance Paris-Saclay, Key Ventures, iX Life, Win4Company.
Quidditas Therapeutics is headquartered in Montlhéry, France.
Quidditas Therapeutics develops an alternative technology which permits an absolute genetic recombination.
Quidditas Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Quidditas Therapeutics — Funding & Investors." VCBacked, May 12, 2025, https://www.vcbacked.co/company/quidditas-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Quidditas Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/quidditas-therapeutics
{{cite web |title=Quidditas Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/quidditas-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated